In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Accepts NDA For Otsuka’s Novel Hyponatremia Treatment

This article was originally published in PharmAsia News

Executive Summary

FDA has accepted Otsuka's new drug application for the investigational V2-vasopressin receptor antagonist tolvaptan, which could enter an increasingly crowded market

You may also be interested in...

Otsuka’s Novel Samska Gets U.S. Advisory Committee Review

U.S. FDA's Cardiovascular and Renal Drugs Advisory Committee will meet June 25 to evaluate Otsuka Pharmaceutical's hyponatremia drug Samska (tolvaptan) for approval in patients with hypervolemic and euvolemic hyponatremia.

Astellas' Vaprisol Receives Second Indication

FDA has approved Astellas Pharma's Vaprisol (conivaptan) for the intravenous treatment of hospitalized patients with hypervolemic hyponatremia, the Japanese company announced March 2

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts